Asterias Biotherapeutics Signs Pact with Cancer Research UK and Cancer Research Technology

According to a media release, AST-VAC2 is a non-patient specific cancer vaccine designed to stimulate patients' immune systems to attack telomerase, a protein that is expressed in over 95 percent of cancers but is rarely expressed in normal adult cells. The vaccine was developed following successful early phase clinical trials of a similar, patient specific Asterias vaccine, called AST-VAC1, which was derived from patients' blood cells and tested in prostate cancer and acute myeloid leukemia.

http://ift.tt/1ryGPe6